Familial and sporadic Porphyria cutanea tarda: Characterization and diagnostic strategies

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 795-803

  Aarsand, Aasne K ^a   Boman, Helge ^b,c   Sandberg, Sverre ^a,b,c  

^a NAPOS   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; CORTISONE; HEPTAPORPHYRIN; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG; UROPORPHYRIN; UROPORPHYRINOGEN DECARBOXYLASE; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CALCULATION; CLINICAL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEMOCHROMATOSIS; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NORWAY; NUCLEOTIDE SEQUENCE; PORPHYRIA CUTANEA TARDA; PREDICTION; PREDICTOR VARIABLE; REGISTRATION; SEX; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MUTATION;

BASE SEQUENCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PORPHYRIA CUTANEA TARDA; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 64149093515     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.117432     Document Type: Article

References (27)

1. Brady JJ, Jackson HA, Roberts AG, Whatley SD, Rowlands GL, Darby C, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the on- set of porphyria cutanea tarda. J Invest Dermatol 2000;115:868-74.
2. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000;95:1565-71.
3. Christiansen L, Bygum A, Jensen A, Brandrup F, Thomsen K, Horder M, Petersen NE. Uroporphy- rinogen decarboxylase gene mutations in Danish patients with porphyria cutanea tarda. Scand J Clin Lab Invest 2000;60:611-5.
4. Koszo F, Morvay M, Dobozy A, Simon N. Eryth- rocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda. Br J Dermatol 1992;126:446-9.
5. Mendez M, Poblete-Gutierrez P, Garcia-Bravo M, Wiederholt T, Moran-Jimenez MJ, Merk HF, et al. Molecular heterogeneity of familial porphyria cu- tanea tarda in Spain: characterization of 10 novel mutations in the UROD gene. Br J Dermatol 2007; 157:501-7.
6. Poblete-Gutierrez P, Mendez M, Wiederholt T, Merk HF, Fontanellas A, Wolff C, Frank J. The molecular basis of porphyria cutanea tarda in Chile: identification and functional characteriza- tion of mutations in the uroporphyrinogen decar- boxylase gene. Exp Dermatol 2004;13:372-9.
7. Tavazzi D, Di Montemuros FM, Fargion S, Fracan- zani AL, Fiorelli G, Cappellini MD. Levels of uro- porphyrinogen decarboxylase (URO-D) in erythro- cytes of Italian porphyria cutanea tarda patients. Cell Mol Biol (Noisy-le-grand) 2002;48:27-32.
8. Deacon AC, Whatley SD, Elder GH. Porphyrins and disorders of porphyrin metabolism. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New York: Elsevier Saunders; 2006. p 1209-35.
9. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67-75.
10. Cappellini MD, Martinez di Montemuros F, Tavazzi D, Fargion S, Pizzuti A, Comino A, et al. Seven novel point mutations in the uroporphy- rinogen decarboxylase (UROD) gene in patients with familial porphyria cutanea tarda (f-PCT). Hum Mutat 2001;17:350.
11. McManus J, Blake D, Ratnaike S. An assay of uroporphyrinogen decarboxylase in erythrocytes. Clin Chem 1988;34:2355-7.
12. Da Silva V, Simonin S, Deybach JC, Puy H, Nor- dmann Y. Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 1995;238:163-8.
13. Uitenbroek GD. Diagnostic effectiveness. SISA; 2002. http://www. quantitativeskills.com/sisa/statistics/diagnos.htm (Accessed July 2008).
14. Leeflang MM, Moons KG, Reitsma JB, Zwinder- man AH. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem 2008;54:729-37.
15. Phillips JD, Parker TL, Schubert HL, Whitby FG, Hill CP, Kushner JP. Functional consequences of naturally occurring mutations in human uro- porphyrinogen decarboxylase. Blood 2001;98: 3179-85.
16. Garey JR, Harrison LM, Franklin KF, Metcalf KM, Radisky ES, Kushner JP. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with por- phyria cutanea tarda. J Clin Invest 1990;86: 1416-22.
17. Andersson C. Acute intermittent porphyria in northern Sweden: a population-based study [The- sis]. Umeå, Sweden: Umeå Universitet, 1997: pp20-1.
18. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corri- gall AV, Roberts AG, et al. A R59W mutation in human protoporphyrinogen oxidase results in de- creased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996;13:95-7.
19. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nor- destgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses in- cluding 66,000 cases and 226,000 controls. Hepatology 2007;46:1071-80.
20. Bygum A, Christiansen L, Petersen NE, Hørder M, Thomsen K, Brandrup F. Familial and sporadic porphyria cutanea tarda: clinical, biochemical and genetic features with emphasis on iron status. Acta Derm Venereol 2003;83:115-20.
21. Harper P, Floderus Y, Holmström P, Eggertsen G, Gåfvels M. Enrichment of HFE mutations in Swed- ish patients with familial and sporadic form of porphyria cutanea tarda. J Intern Med 2004;255: 684-8.
22. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sider- oblastic anemia and the porphyrias. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, Vogelstein B, eds. The metabolic and molec- ular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p 2961-3062.
23. Stolzel U, Köstler E, Schuppan D, Richter M, Wollina U, Doss MO, et al. Hemochromatosis (HFE) gene mutations and response to chloro- quine in porphyria cutanea tarda. Arch Dermatol 2003;139:309-13.
24. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002;48:1891-900.
25. Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Gene dosage an- alysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria. J Invest Dermatol 2007;127: 2790-4.
26. Human Gene Mutation Database. HGMD profes- sional release 2008.1. https://portal.biobase- international.com/hgmd/pro/gene.php?geneUROD (Accessed July 2008). Accessed through BIO- BASE Biological Databases: http://www.biobase- international.com/.
27. Ensembl. http://www.ensembl.org/(Accessed July 2008). This Web site provides a genome browser.